CREB3L1 and breast neoplasm: Moreover, patients with reduced CREB3L1 expression have a shorter relapse-free survival as compared to patients with breast tumors expressing CREB3L1, particularly for the luminal A (p = 8.8 x 10−6) and TNBC (p = 0.038) subtypes [13].